Jiangsu Hengrui Medicine has filed a patent for a sulfur-containing isoindoline derivative, which can be used as a therapeutic agent for the treatment of multiple myeloma. The compound, represented by general formula (I), and its preparation method are disclosed in the patent application. GlobalData’s report on Jiangsu Hengrui Medicine gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Jiangsu Hengrui Medicine, Cancer treatment biomarkers was a key innovation area identified from patents. Jiangsu Hengrui Medicine's grant share as of September 2023 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Sulfur-containing isoindoline derivative for treatment of multiple myeloma
A recently filed patent (Publication Number: US20230257366A1) describes a compound of general formula (I) and its various forms, including tautomers, mesomers, racemates, enantiomers, diastereomers, and mixtures thereof, as well as pharmaceutically acceptable salts. The compound also includes a specific structure known as general formula (II) or its various forms, along with pharmaceutically acceptable salts. The patent further specifies that the compound can have a phenyl or 5- to 6-membered heteroaryl ring (ring A) and a 3- to 8-membered heterocyclyl ring (ring B). The compound can have different substituents, such as halogen, alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, which can be further substituted with various groups like halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, and hydroxyalkyl.
The patent also discloses a method for preparing the compound of general formula (I) and its various forms, as well as pharmaceutically acceptable salts. Additionally, it describes a pharmaceutical composition containing the compound and one or more pharmaceutically acceptable carriers, diluents, or excipients. The patent further claims a method for treating and/or preventing various medical conditions, including cancer, angiogenesis-related disorders, pain, macular degeneration, skin diseases, pulmonary diseases, asbestos-related diseases, parasitic diseases, immunodeficiency diseases, CNS diseases, CNS injuries, atherosclerosis, sleep disorders, infectious diseases, hemoglobinopathies, and TNFa-related disorders. The method involves administering an effective amount of the compound or its various forms, as well as pharmaceutically acceptable salts, to a subject in need.
Specifically, the patent mentions that the method can be used to treat cancers such as leukemia, myeloma, lymphoma, melanoma, liver cancer, lung cancer, breast cancer, prostate cancer, and various other types of cancer. It also includes the treatment of multiple myeloma (MM) and myelodysplastic syndrome (MDS), particularly in cases of relapsed, refractory, or resistant multiple myeloma.
In summary, the patent describes a compound of general formula (I) and its various forms, along with a specific structure known as general formula (II), and their use in pharmaceutical compositions and methods for treating various medical conditions, including cancer and other diseases.
To know more about GlobalData’s detailed insights on Jiangsu Hengrui Medicine, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
